CMPS today
$9.30+$0.05 (+0.54%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourBearish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $15.87
Key levels
Resistance$10.94
Resistance$9.83
Support$8.90
Support$7.54
Latest news & SEC filings
AnalystRBC Capital keeps Buy rating on COMPASS Pathways
ProductCOMPASS Pathways finishes NDA submission for COMP360 psilocybin
ProductCompass Pathways seeks US approval for psilocybin therapy in treatment-resistant depression
AnalystHC Wainwright Reiterates Buy Rating on Compass Pathways With $65 Price Target
All CMPS news →About Compass Pathways
Compass Pathways is a biotech firm working on psilocybin-based therapies for psychiatric illness. Its main candidate, COMP360, is being tested in late-stage human studies for depression that has not responded to other drugs, and in mid-stage studies for trauma-related stress disorder. The company holds worldwide rights to develop and sell the treatment and is preparing for a possible launch in the United States.
Based on the company's 10-K filed Mar 24, 2026.
Nasdaq · Healthcare
COMPASS Pathways plc (CMPS)
What Is the Price Target for CMPS?
SEPT Low Target
$10.00
SEPT Mid Target
$20.50
SEPT High Target
$65.00
Analyst Consensus
$20.50
Is CMPS a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CMPS.
Start Free Trial →Is CMPS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$20.50
0
Moat Score
NONE
1/9
Piotroski Score
-6.8
Altman Z-Score
What Is Smart Money Doing with CMPS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Nath Kabir | director officer | Sale | 5,962 | $67K | Aug 3, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CMPS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-33.91%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for CMPS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CMPS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:37:45 | $9.27 | 1,820 | $$17K | SELL |
| 21:31:45 | $9.28 | 1,199 | $$11K | SELL |
| 21:00:46 | $9.30 | 8,980 | $$84K | MIDPOINT |
| 21:00:46 | $9.30 | 1,315 | $$12K | MIDPOINT |
| 21:00:45 | $9.30 | 2,665 | $$25K | MIDPOINT |
5 dark pool trades shown · $$149K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CMPS
PREVIEWSEPT Investing provides real-time options flow tracking for CMPS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $12 | Feb 19 | 100 | $$800 | 10 | SWEEP |
| CALL | $12 | Feb 19 | 100 | $$400 | 5 | SWEEP |
| CALL | $12 | Feb 19 | 100 | $$2400 | 30 | SWEEP |
| CALL | $12 | Feb 19 | 100 | $$3360 | 42 | SWEEP |
| CALL | $12 | Feb 19 | 100 | $$240 | 3 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for COMPASS Pathways plc (CMPS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CMPS — frequently asked questions
What is CMPS stock price today?
COMPASS Pathways plc (CMPS) is at $9.30, up 0.54% (+$0.05) at the Nov 11, 2026 close.
Why is CMPS stock moving today?
Latest CMPS news — Nov 10, 2026: RBC Capital keeps Buy rating on COMPASS Pathways · Nov 9, 2026: COMPASS Pathways finishes NDA submission for COMP360 psilocybin
What is the CMPS price target?
The average analyst price target for CMPS is $20.50, ranging from $10 to $65, based on 12 analysts.
What do analysts rate CMPS?
Analyst ratings for CMPS: 1 Buy, 21 Hold, 0 Sell — consensus Hold.
Did CMPS beat earnings?
CMPS last reported on Nov 3, 2026: EPS -$0.31 vs -$0.39 expected — a beat of 20.5%.
Does CMPS pay a dividend?
CMPS does not currently pay a dividend.
How much debt does CMPS have?
COMPASS Pathways plc reported $51M of debt and $444M of cash (Sep 30, 2026).
What are CMPS support and resistance levels?
Support: $8.90, $7.54, $6.27. Resistance: $9.83, $10.94, $12.50.
What are insiders doing with CMPS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on CMPS?
Nov 10, 2026: RBC Capital keeps Buy rating on COMPASS Pathways · Nov 9, 2026: COMPASS Pathways finishes NDA submission for COMP360 psilocybin · Nov 9, 2026: Compass Pathways seeks US approval for psilocybin therapy in treatment-resistant depression